Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight analysts that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $21.3333.Get Theravance Biopharma alerts:A number of analysts have recently issued reports on TBPH shares. BTIG Research reiterated a "buy" rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. HC Wainwright increased their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Sunday. Oppenheimer lowered shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating in a research note on Thursday, March 5th. Finally, B. Riley Financial reissued a "neutral" rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th.Check Out Our Latest Stock Analysis on TBPHTheravance Biopharma Stock PerformanceNASDAQ TBPH opened at $15.26 on Tuesday. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $21.03. The stock's 50 day moving average price is $17.40 and its two-hundred day moving average price is $16.94. The stock has a market capitalization of $785.74 million, a price-to-earnings ratio of 7.52 and a beta of 0.17. Insider ActivityIn related news, SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company's stock. Institutional Inflows and OutflowsInstitutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company's stock worth $32,289,000 after purchasing an additional 54,152 shares in the last quarter. State Street Corp grew its stake in shares of Theravance Biopharma by 4.4% in the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company's stock valued at $20,616,000 after buying an additional 45,987 shares in the last quarter. Geode Capital Management LLC increased its holdings in Theravance Biopharma by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company's stock worth $17,567,000 after buying an additional 40,734 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Theravance Biopharma by 12.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company's stock worth $16,072,000 after buying an additional 92,253 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma during the third quarter worth $10,611,000. Institutional investors and hedge funds own 99.10% of the company's stock. Theravance Biopharma Company Profile (Get Free Report)Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.Recommended StoriesFive stocks we like better than Theravance BiopharmaThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Theravance Biopharma Right Now?Before you consider Theravance Biopharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here